Proven efficacy in patients with wet AMD 1-3

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD).

MARINA and ANCHOR

HARBOR

Dosing and Safety

Resources
Resources for your patients.
LUCENTIS Direct
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Access and reimbursement services for your patients.